PeptiDream has developed a technology to create cyclic peptides. Which of the following is TRUE about the technology they developed? O They adopted Antisense Technology to incorporate cyclic peptides to the antisense drug which has improved therapeutic effect. O They utilized HTPathwaySeq, which is an RNA-seq based drug screening platform to characterize therapeutic molecules including cyclic peptides O They combine the technology of mRNA display and Flexizyme to put an unnatural amino acid onto a tRNA which goes into the in vitro translation system O They took advantage of the SYNTHORUNTM Technology Platform, which expands the genetic code by adding a new DNA base pair in order to incorporate unnatural amino acid.

PeptiDream has developed a technology to create cyclic peptides. Which of the following is TRUE about the technology they developed? O They adopted Antisense Technology to incorporate cyclic peptides to the antisense drug which has improved therapeutic effect. O They utilized HTPathwaySeq, which is an RNA-seq based drug screening platform to characterize therapeutic molecules including cyclic peptides O They combine the technology of mRNA display and Flexizyme to put an unnatural amino acid onto a tRNA which goes into the in vitro translation system O They took advantage of the SYNTHORUNTM Technology Platform, which expands the genetic code by adding a new DNA base pair in order to incorporate unnatural amino acid.

Name: PeptiDream has developed a technology to create cyclic peptides. Whic
Uploaded: 2024-03-20T06:42:41.000Z
Channel: Bartleby
Description: PeptiDream has developed a technology to create cyclic peptides. Which of the following is TRUEabout the technology they developed?O They adopted Antisense Technology to incorporate cyclic peptides to the antisense drug which has improvedtherapeutic

Human Heredity: Principles and Issues (MindTap Course List)

11th Edition

ISBN:9781305251052

Author:Michael Cummings

Publisher:Michael Cummings

Chapter16: Reproductive Technology, Genetic Testing, And Gene Therapy

Section: Chapter Questions

Problem 13QP: The prospect of using gene therapy to alleviate genetic conditions is still a vision of the future....

See similar textbooks

Similar questions

The prospect of using gene therapy to alleviate genetic conditions is still a vision of the future. Gene therapy for adenosine deaminase deficiency has proved to be quite promising, but many obstacles remain to be overcome. Currently, the correction of human genetic defects is done using retroviruses as vectors. For this purpose, viral genes are removed from the retroviral genome, creating a vector capable of transferring human structural genes into sites on human chromosomes within target-tissue cells. Do you see any potential problems with inserting pieces of a retroviral genome into humans? If so, are there ways to combat or prevent these problems?
Why is the bradford assay method using BSA sensitive ? and how does it compare to the amino acid analysis method
BiDil® is indicated for the treatment of heart failure as an adjunct to standard therapy in self-identified black patients to improve survival, to prolong time to hospitalization for heart failure, and to improve patient-reported functional status Question: The results of BiDil® clinical trials were compelling…Expound on the results. Question : What role did FDA’s approval resulted in BiDil® being a great example of pharmacogenomics/pharmacogenetics in the U.S.?
What are 2 main challenges of protein targeting ? Then describe one way these challenges are overcome during signal-based targeting and one way they are overcome during vesicle-based targeting .
Salmonella strains developed for the Ames test contain many special phenotypes that make them more useful for these techniques. Many of these phenotypes, including UvrA and rfa, make these strains mutate more easily, and therefore make the assays more sensitive. In 1-2 sentences each, state how the UvrA and rfa phenotypes make Ames test strains more sensitive to mutations.
Northern blots are valuable tools to analyze the mRNA level present in a sample. Describe an experiment that uses the Northern blot as a tool and how you would visualize the mRNA giving at least two examples of probe types.
You are employed in a gene therapy laboratory to test the effectiveness of a vector for correcting the DF508 –CFTR mutation. The vector uses CRISPR –CAS9 genome editing to correct the mutated gene in situ (CFTR-CRISPR). An Ussing chamber experiment was performed using nasal airway cells obtained from a patient with the DF508 CFTR mutation which were transformed with either a control vector consisting of an inert CRISPR-CAS-9 construct (CONTROL) or the active, gene correcting CRISPR CAS-9 construct (CFTR-CRISPR). The following transepithelial voltage values were obtained for the drug regimen shown under open circuit and current clamp (injected current of 10mA) conditions: CONTROL Baseline Amiloride Forskolin Inh172 Vte (mV) -78 -2 -4 -3 DVRt (mV) 8 16 7.5 13 R (W.cm-2) 800 1600 750 1300 I (mA.cm-2) 98 1 5 2 CFTR-CRISPR Vte (mV) -38 -6 -23 -9 DVRt (mV) 9 27 6 11 R (W.cm-2) 900 2700 600…
You are employed in a gene therapy laboratory to test the effectiveness of a vector for correcting the DF508 –CFTR mutation. The vector uses CRISPR –CAS9 genome editing to correct the mutated gene in situ (CFTR-CRISPR). An Ussing chamber experiment was performed using nasal airway cells obtained from a patient with the DF508 CFTR mutation which were transformed with either a control vector consisting of an inert CRISPR-CAS-9 construct (CONTROL) or the active, gene correcting CRISPR CAS-9 construct (CFTR-CRISPR). The following transepithelial voltage values were obtained for the drug regimen shown under open circuit and current clamp (injected current of 10mA) conditions: CONTROL Baseline Amiloride Forskolin Inh172 Vte (mV) -78 -2 -4 -3 DVRt (mV) 8 16 7.5 13 R (W.cm-2) 800 1600 750 1300 I (mA.cm-2) 98 1 5 2 CFTR-CRISPR Vte (mV) -38 -6 -23 -9 DVRt (mV) 9 27 6 11 R (W.cm-2) 900 2700 600…
You are employed in a gene therapy laboratory to test the effectiveness of a vector for correcting the DF508 –CFTR mutation. The vector uses CRISPR –CAS9 genome editing to correct the mutated gene in situ (CFTR-CRISPR). An Ussing chamber experiment was performed using nasal airway cells obtained from a patient with the DF508 CFTR mutation which were transformed with either a control vector consisting of an inert CRISPR-CAS-9 construct (CONTROL) or the active, gene correcting CRISPR CAS-9 construct (CFTR-CRISPR). The following transepithelial voltage values were obtained for the drug regimen shown under open circuit and current clamp (injected current of 10mA) conditions: CONTROL Baseline Amiloride Forskolin Inh172 Vte (mV) -78 -2 -4 -3 DVRt (mV) 8 16 7.5 13 R (W.cm-2) 800 1600 750 1300 I (mA.cm-2) 98 1 5 2 CFTR-CRISPR Vte (mV) -38 -6 -23 -9 DVRt (mV) 9 27 6 11 R (W.cm-2) 900 2700 600…
You are employed in a gene therapy laboratory to test the effectiveness of a vector for correcting the DF508 –CFTR mutation. The vector uses CRISPR –CAS9 genome editing to correct the mutated gene in situ (CFTR-CRISPR). An Ussing chamber experiment was performed using nasal airway cells obtained from a patient with the DF508 CFTR mutation which were transformed with either a control vector consisting of an inert CRISPR-CAS-9 construct (CONTROL) or the active, gene correcting CRISPR CAS-9 construct (CFTR-CRISPR). The following transepithelial voltage values were obtained for the drug regimen shown under open circuit and current clamp (injected current of 10mA) conditions: CONTROL Baseline Amiloride Forskolin Inh172 Vte (mV) -78 -2 -4 -3 DVRt (mV) 8 16 7.5 13 R (W.cm-2) 800 1600 750 1300 I (mA.cm-2) 98 1 5 2 CFTR-CRISPR Vte (mV) -38 -6 -23 -9 DVRt (mV) 9 27 6 11 R (W.cm-2) 900 2700 600…
You are employed in a gene therapy laboratory to test the effectiveness of a vector for correcting the DF508 –CFTR mutation. The vector uses CRISPR –CAS9 genome editing to correct the mutated gene in situ (CFTR-CRISPR). An Ussing chamber experiment was performed using nasal airway cells obtained from a patient with the DF508 CFTR mutation which were transformed with either a control vector consisting of an inert CRISPR-CAS-9 construct (CONTROL) or the active, gene correcting CRISPR CAS-9 construct (CFTR-CRISPR). The following transepithelial voltage values were obtained for the drug regimen shown under open circuit and current clamp (injected current of 10mA) conditions: CONTROL Baseline Amiloride Forskolin Inh172 Vte (mV) -78 -2 -4 -3 DVRt (mV) 8 16 7.5 13 R (W.cm-2) 800 1600 750 1300 I (mA.cm-2) 98 1 5 2 CFTR-CRISPR Vte (mV) -38 -6 -23 -9 DVRt (mV) 9 27 6 11 R (W.cm-2) 900 2700 600…
You are employed in a gene therapy laboratory to test the effectiveness of a vector for correcting the DF508 –CFTR mutation. The vector uses CRISPR –CAS9 genome editing to correct the mutated gene in situ (CFTR-CRISPR). An Ussing chamber experiment was performed using nasal airway cells obtained from a patient with the DF508 CFTR mutation which were transformed with either a control vector consisting of an inert CRISPR-CAS-9 construct (CONTROL) or the active, gene correcting CRISPR CAS-9 construct (CFTR-CRISPR). The following transepithelial voltage values were obtained for the drug regimen shown under open circuit and current clamp (injected current of 10mA) conditions: CONTROL Baseline Amiloride Forskolin Inh172 Vte (mV) -78 -2 -4 -3 DVRt (mV) 8 16 7.5 13 R (W.cm-2) 800 1600 750 1300 I (mA.cm-2) 98 1 5 2 CFTR-CRISPR Vte (mV) -38 -6 -23 -9 DVRt (mV) 9 27 6 11 R (W.cm-2) 900 2700 600…